Selective adaptation with reversible figures: Don’t change that channel

Thomas C. Toppino,G. Long

DOI: https://doi.org/10.3758/BF03211512

Perception & Psychophysics

Abstract:

What problem does this paper attempt to address?

Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP: Report from an International DLBCL Rituximab-CHOP Consortium Program Study

Zijun Y. Xu-Monette,Lin Wu,Carlo Visco,Yu Chuan Tai,Alexander Tzankov,Wei-min Liu,Santiago Montes-Moreno,Karen Dybkaer,April Chiu,Attilio Orazi,Youli Zu,Govind Bhagat,Kristy L. Richards,Eric D. Hsi,X. Frank Zhao,William W. L. Choi,Xiaoying Zhao,J. Han van Krieken,Qin Huang,Jooryung Huh,Weiyun Ai,Maurilio Ponzoni,Andres J. M. Ferreri,Fan Zhou,Brad S. Kahl,Jane N. Winter,Wei Xu,Jianyong Li,Ronald S. Go,Yong Li,Miguel A. Piris,Michael B. Moller,Roberto N. Miranda,Lynne V. Abruzzo,L. Jeffrey Medeiros,Ken H. Young

DOI: https://doi.org/10.1182/blood-2012-05-433334

IF: 20.3

2012-01-01

Blood

Abstract:TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (CHOP) therapy. However, its prognostic value in the rituximab immunochemotherapy era remains undefined. In the present study of a large cohort of DLBCL patients treated with rituximab plus CHOP (R-CHOP), we show that those with TP53 mutations had worse overall and progression-free survival compared with those without. Unlike earlier studies of patients treated with CHOP, TP53 mutation has predictive value for R-CHOP-treated patients with either the germinal center B-cell or activated B-cell DLBCL subtypes. Furthermore, we identified the loop-sheet-helix and L3 motifs in the DNA-binding domain to be the most critical structures for maintaining p53 function. In contrast, TP53 deletion and loss of heterozygosity did not confer worse survival. If gene mutation data are not available, immunohistochemical analysis showing > 50% cells expressing p53 protein is a useful surrogate and was able to stratify patients with significantly different prognoses. We conclude that assessment of TP53 mutation status is important for stratifying R-CHOP-treated patients into distinct prognostic subsets and has significant value in the design of future therapeutic strategies.
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—2024 update

Jitka Malcikova,Sarka Pavlova,Panagiotis Baliakas,Thomas Chatzikonstantinou,Eugen Tausch,Mark Catherwood,Davide Rossi,Thierry Soussi,Boris Tichy,Arnon P. Kater,Carsten U. Niemann,Frederic Davi,Gianluca Gaidano,Stephan Stilgenbauer,Richard Rosenquist,Kostas Stamatopoulos,Paolo Ghia,Sarka Pospisilova

DOI: https://doi.org/10.1038/s41375-024-02267-x

2024-05-17

Leukemia

Abstract:In chronic lymphocytic leukemia (CLL), analysis of TP53 aberrations (deletion and/or mutation) is a crucial part of treatment decision-making algorithms. Technological and treatment advances have resulted in the need for an update of the last recommendations for TP53 analysis in CLL, published by ERIC, the European Research Initiative on CLL, in 2018. Based on the current knowledge of the relevance of low-burden TP53 -mutated clones, a specific variant allele frequency (VAF) cut-off for reporting TP53 mutations is no longer recommended, but instead, the need for thorough method validation by the reporting laboratory is emphasized. The result of TP53 analyses should always be interpreted within the context of available laboratory and clinical information, treatment indication, and therapeutic options. Methodological aspects of introducing next-generation sequencing (NGS) in routine practice are discussed with a focus on reliable detection of low-burden clones. Furthermore, potential interpretation challenges are presented, and a simplified algorithm for the classification of TP53 variants in CLL is provided, representing a consensus based on previously published guidelines. Finally, the reporting requirements are highlighted, including a template for clinical reports of TP53 aberrations. These recommendations are intended to assist diagnosticians in the correct assessment of TP53 mutation status, but also physicians in the appropriate understanding of the lab reports, thus decreasing the risk of misinterpretation and incorrect management of patients in routine practice whilst also leading to improved stratification of patients with CLL in clinical trials.

oncology,hematology
UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants

Helen Hanson,Angela F Brady,Gillian Crawford,Rosalind A Eeles,Sarah Gibson,Mette Jorgensen,Louise Izatt,Aslam Sohaib,Marc Tischkowitz,D Gareth Evans,Muna Ahmed,Paola Angelini,Paul Brennan,Carole Brewer,Jackie Cook,Rosemarie Davidson,Mark Davis,Bianca de Souza,Verity Easton,Ian Frayling,Angela George,Andrew Gogbashian,Vicky Goh,Andrew Green,Lynn Greenhalgh,Michael Farrell,Dorothy Halliday,Rosalyn Jewell,Robin Jones,Claire Lloyd,Baharak Mohammadi,Alex Murray,Kai Ren Ong,Erika Pace,Pan Pantziarka,Michelle Potter,Sarah Pugh,Gillian Rea,Beverley Speight,Stavros Stivros,David Swienton,Clare Turnbull,Leslie Walker,Richard Whitehouse

DOI: https://doi.org/10.1136/jmedgenet-2020-106876

2020-06-22

Journal of Medical Genetics

Abstract:Constitutional pathogenic variants in TP53 are associated with Li-Fraumeni syndrome or the more recently described heritable TP53- related cancer syndrome and are associated with increased lifetime risks of a wide spectrum of cancers. Due to the broad tumour spectrum, surveillance for this patient group has been limited. To date, the only recommendation in the UK has been for annual breast MRI in women; however, more recently, a more intensive surveillance protocol including whole-body MRI (WB-MRI) has been recommended by International Expert Groups. To address the gap in surveillance for this patient group in the UK, the UK Cancer Genetics Group facilitated a 1-day consensus meeting to discuss a protocol for the UK. Using a preworkshop survey followed by structured discussion on the day, we achieved consensus for a UK surveillance protocol for TP53 carriers to be adopted by UK Clinical Genetics services. The key recommendations are for annual WB-MRI and dedicated brain MRI from birth, annual breast MRI from 20 years in women and three-four monthly abdominal ultrasound in children along with review in a dedicated clinic.

genetics & heredity
Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis

Yen-Chun Liu,Elizabeth Margolskee,John N. Allan,Susan Mathew,Erica Bhavsar,Joseph Casano,Attilio Orazi,Richard R. Furman,Julia T. Geyer

DOI: https://doi.org/10.1038/s41379-019-0356-z

IF: 8.209

2019-09-02

Modern Pathology

Abstract:TP53 alteration in chronic lymphocytic leukemia indicates a high-risk disease that is usually refractory to chemotherapy. It may be caused by deletion of 17p involving the loss of TP53 gene, which occurs in low percentage of patients at diagnosis but can be acquired as the disease progresses. Since patients may harbor TP53 mutation without chromosome 17p deletion, consensus recommendations call for both cytogenetic and PCR mutation analysis of TP53 in chronic lymphocytic leukemia. We conducted a single-institution retrospective study to investigate the clinicopathologic features of chronic lymphocytic leukemia with TP53 alterations as well as the utility of different diagnostic modalities to identify p53 alterations. Forty percent of chronic lymphocytic leukemia patients with TP53 alterations demonstrated atypical lymphocytes with cleaved/irregularly shaped nuclei and/or large atypical lymphoid cells with abundant cytoplasm in the peripheral blood. Progression was also observed in lymph node and bone marrow samples (21% with Richter transformation; 33% with findings suggestive of "accelerated phase" of chronic lymphocytic leukemia including prominent proliferation centers and/or increased numbers of prolymphocytes). However, the presence of the morphologic features suggestive of "accelerated phase" had no effect on overall survival within the chronic lymphocytic leukemia group with TP53 abnormalities (p > 0.05). As previously reported by others, a subset of patients with TP53 alterations were only identified by either PCR mutation analysis (12%) or cytogenetic studies (14%). p53 immunostain positivity was only identified in approximately half of the patients with TP53 alterations identified by either method, and it failed to identify any additional patients with p53 abnormalities. In summary, chronic lymphocytic leukemia patients with TP53 alterations frequently show atypical morphologic features. Use of multiple modalities to identify p53 abnormalities is recommended to ensure optimal sensitivity and specificity.

pathology
TP53 Germline Variations Influence the Predisposition and Prognosis of Acute Lymphoblastic Leukemia in Children

Maoxiang Qian,Xueyuan Cao,Meenakshi Devidas,Wenjian Yang,Cheng,Andrew Carroll,Nyla A. Heerema,Hui Zhang,Takaya Moriyama,Julie M. Gastier-Foster,Heng Xu,Elizabeth A. Raetz,Eric Larsen,Naomi Winick,W. Paul Bowman,Paul L. Martin,Elaine R. Mardis,Robert Fulton,Gerard Zambetti,Michael Borowitz,Brent Wood,Kim E. Nichols,William L. Carroll,Ching-Hon Pui,Charles G. Mullighan,William E. Evans,Stephen P. Hunger,Mary V. Relling,Mignon L. Loh,Jun J. Yang

DOI: https://doi.org/10.1200/jco.2017.75.5215

IF: 20.3

2017-01-01

Blood

Abstract:Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that this type of leukemia is another manifestation of Li-Fraumeni syndrome; however, the pattern, prevalence, and clinical relevance of TP53 variants in childhood ALL remain unknown. Patients and Methods Targeted sequencing of TP53 coding regions was performed in 3,801 children from the Children's Oncology Group frontline ALL clinical trials, AALL0232 and P9900. TP53 variant pathogenicity was evaluated according to experimentally determined transcriptional activity, in silico prediction of damaging effects, and prevalence in non-ALL control populations. TP53 variants were analyzed for their association with ALL presenting features and treatment outcomes. Results We identified 49 unique nonsilent rare TP53 coding variants in 77 (2.0%) of 3,801 patients sequenced, of which 22 variants were classified as pathogenic. TP53 pathogenic variants were significantly over-represented in ALL compared with non-ALL controls (odds ratio, 5.2; P < .001). Children with TP53 pathogenic variants were significantly older at ALL diagnosis (median age, 15.5 years v 7.3 years; P < .001) and were more likely to have hypodiploid ALL (65.4% v 1.2%; P < .001). Carrying germline TP53 pathogenic variants was associated with inferior event-free survival and overall survival (hazard ratio, 4.2 and 3.9; P < .001 and .001, respectively). In particular, children with TP53 pathogenic variants were at a dramatically higher risk of second cancers than those without pathogenic variants, with 5-year cumulative incidence of 25.1% and 0.7% ( P < .001), respectively. Conclusion Loss-of-function germline TP53 variants predispose children to ALL and to adverse treatment outcomes with ALL therapy, particularly the risk of second malignant neoplasms.
Germline p.R181H variant in TP53 in a family exemplifying the genotype-phenotype correlations in Li-Fraumeni syndrome

Claire Freycon,Laura Palma,Crystal Budd,Frederic Coulombe,Leora Witkowski,Pierre Hainaut,William D Foulkes,Catherine Goudie

DOI: https://doi.org/10.1007/s10689-024-00419-7

2024-09-11

Abstract:Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with germline pathogenic/likely pathogenic variants in TP53. Genotype-phenotype correlations are progressively being characterized in LFS with certain TP53 variants associated with attenuated penetrance and phenotypes. We report on a family harboring a TP53 p.R181H variant presenting with a restricted cancer phenotype in adulthood. The proband was a female with breast cancer at the age of 71 years who had three first degree relatives also diagnosed with breast cancer after the age of 40 years (mother, two sisters). Of the nine individuals harboring the variant (6 genetically confirmed, 3 obligate heterozygous), six have not developed malignancies at this time (age range: 36-42). No childhood-onset cancers were reported in this family. A concomitant literature review identified 51 additional individuals harboring the p.R181H variant in TP53, presenting a tumor phenotype dominated by breast cancer. Rare occurrences of other adult-onset cancers (prostate, colorectal and thyroid) and only few childhood onset cancer were documented. These observations are consistent with functional analysis showing that p.R181H retains partial p53 function and suggesting possible reduced cancer penetrance, particularly in the pediatric setting.
Case report: TP53 c.848G>A germline mutation as a possible screening target at initial diagnosis for acute lymphoblastic leukemia

Fang Hua,Yue Hu,Guang-Cui He,Si-Han Lai,Ying He,Shan Zhang,Yan Deng,Ying Han,Xiao-Dong Liu,Kun Yang,Hui-Xiu Zhong,Jian Xiao,Zhong-Zheng Zheng,Hai Yi

DOI: https://doi.org/10.1080/16078454.2024.2377860

IF: 2.264

Hematology

Abstract:Backgroud: Li-Fraumeni syndrome is a hereditary tumor syndrome characterized by an elevated risk of malignancy, particularly acute lymphoblastic leukemia (ALL), which can be caused by the heterozygous germline mutation. TP53 gene germline mutation is considered a potential risk factor and crucial prognostic parameter for acute leukemia development and diagnosis, but rarely occurs in adults, and its specific pathogenic significance in acute leukemia is unclear. Case presentation: We describes a case of a 45-year-old woman diagnosed with ALL. Whole-exome sequencing approach identified one of the TP53 germline mutations from her bone marrow sample with possible pathogenic significance, c.848G>A (p.Arg283His) heterozygous missense mutation located on exon 8, which was further verified in her hair, oral mucous and nail samples. Family pedigree screening revealed that the same TP53 genetic variant was present in the patient's father and non-donor son, whereas not in the donor. Digital PCR observed that this point mutation frequency dropped post-transplantation but remained low during maintenance therapy when the patient was leukemia-free. Conclusion: This suspected Li-Fraumeni syndrome case report with a likely pathogenic heterozygous TP53 variant expands the cancer genetic spectrum. Screening her family members for mutations facilitates identifying the optimal relative donor and avoids unnecessary treatment by monitoring TP53 germline mutations for minimal residual disease following hematopoietic stem cell transplantation. Its potential roles in hematological malignant tumor development and clinical pathogenic implications necessitate further probing.
Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum

Cristina Fortuno,Bing-Jian Feng,Courtney Carroll,Giovanni Innella,Wendy Kohlmann,Conxi Lázaro,Joan Brunet,Lidia Feliubadaló,Silvia Iglesias,Mireia Menéndez,Alex Teulé,Mandy L. Ballinger,David M. Thomas,Ainsley Campbell,Mike Field,Marion Harris,Judy Kirk,Nicholas Pachter,Nicola Poplawski,Rachel Susman,Kathy Tucker,Mathew Wallis,Rachel Williams,Elisa Cops,David Goldgar,Paul A. James,Amanda B. Spurdle,David Amor,Lesley Andrews,Yoland Antill,Rosemary Balleine,Jonathan Beesley,Ian Bennett,Michael Bogwitz,Simon Bodek,Leon Botes,Meagan Brennan,Melissa Brown,Michael Buckley,Jo Burke,Phyllis Butow,Liz Caldon,Ian Campbell,Michelle Cao,Anannya Chakrabarti,Deepa Chauhan,Manisha Chauhan,Georgia Chenevix-Trench,Alice Christian,Paul Cohen,Alison Colley,Ashley Crook,James Cui,Eliza Courtney,Margaret Cummings,Sarah-Jane Dawson,Anna deFazio,Martin Delatycki,Rebecca Dickson,Joanne Dixon,Ted Edkins,Stacey Edwards,Gelareh Farshid,Andrew Fellows,Georgina Fenton,Michael Field,James Flanagan,Peter Fong,Laura Forrest,Stephen Fox,Juliet French,Michael Friedlander,Clara Gaff,Mike Gattas,Peter George,Sian Greening,Marion Harris,Stewart Hart,Nick Hayward,John Hopper,Cass Hoskins,Clare Hunt,Paul James,Mark Jenkins,Alexa Kidd,Judy Kirk,Jessica Koehler,James Kollias,Sunil Lakhani,Mitchell Lawrence,Jason Lee,Shuai Li,Geoff Lindeman,Jocelyn Lippey,Lara Lipton,Liz Lobb,Sherene Loi,Graham Mann,Deborah Marsh,Sue Anne McLachlan,Bettina Meiser,Roger Milne,Sophie Nightingale,Shona O'Connell,Sarah O'Sullivan,David Gallego Ortega,Nick Pachter,Jia-Min Pang,Gargi Pathak,Briony Patterson,Amy Pearn,Kelly Phillips,Ellen Pieper,Susan Ramus,Edwina Rickard,Bridget Robinson,Mona Saleh,Anita Skandarajah,Elizabeth Salisbury,Christobel Saunders,Jodi Saunus,Peter Savas,Rodney Scott,Clare Scott,Adrienne Sexton,Joanne Shaw,Andrew Shelling,Shweta Srinivasa,Peter Simpson,Melissa Southey,Amanda Spurdle,Jessica Taylor,Renea Taylor,Heather Thorne,Alison Trainer,Kathy Tucker,Jane Visvader,Logan Walker,Rachael Williams,Ingrid Winship,Mary Ann Young,Milita Zaheed,

DOI: https://doi.org/10.1200/po.23.00453

2024-02-01

JCO Precision Oncology

Abstract:PURPOSE Establishing accurate age-related penetrance figures for the broad range of cancer types that occur in individuals harboring a pathogenic germline variant in the TP53 gene is essential to determine the most effective clinical management strategies. These figures also permit optimal use of cosegregation data for classification of TP53 variants of unknown significance. Penetrance estimation can easily be affected by bias from ascertainment criteria, an issue not commonly addressed by previous studies. MATERIALS AND METHODS We performed a maximum likelihood penetrance estimation using full pedigree data from a multicenter study of 146 TP53-positive families, incorporating adjustment for the effect of ascertainment and population-specific background cancer risks. The analysis included pedigrees from Australia, Spain, and United States, with phenotypic information for 4,028 individuals. RESULTS Core Li-Fraumeni syndrome (LFS) cancers (breast cancer, adrenocortical carcinoma, brain cancer, osteosarcoma, and soft tissue sarcoma) had the highest hazard ratios of all cancers analyzed in this study. The analysis also detected a significantly increased lifetime risk for a range of cancers not previously formally associated with TP53 pathogenic variant status, including colorectal, gastric, lung, pancreatic, and ovarian cancers. The cumulative risk of any cancer type by age 50 years was 92.4% (95% CI, 82.2 to 98.3) for females and 59.7% (95% CI, 39.9 to 81.3) for males. Females had a 63.3% (95% CI, 35.6 to 90.1) cumulative risk of developing breast cancer by age 50 years. CONCLUSION The results from maximum likelihood analysis confirm the known high lifetime risk for the core LFS-associated cancer types providing new risk estimates and indicate significantly increased lifetime risks for several additional cancer types. Accurate cancer risk estimates will help refine clinical recommendations for TP53 pathogenic variant carriers and improve TP53 variant classification.

oncology
Abstract 6198: TP53 mutational clusters stratify the Li-Fraumeni syndrome spectrum

Nicholas W. Fischer,Brianne Laverty,Ran Kafri,Kara N. Maxwell,Emma R. Woodward,Christian Kratz,David Malkin

DOI: https://doi.org/10.1158/1538-7445.am2024-6198

IF: 11.2

2024-03-24

Cancer Research

Abstract:Li-Fraumeni syndrome (LFS) is a highly penetrant cancer predisposition disorder caused by germline variants in the TP53 tumor suppressor gene. LFS has recently been redefined as a 'spectrum' disorder to reflect the highly variable cancer types with largely unpredictable ages-of-onset and disease severity. The broad functional gradient associated with different TP53 variants is thought to contribute to LFS heterogeneity, although it is still poorly understood and there is an unmet clinical need for risk stratification strategies to improve variant interpretation and patient care. Here, we performed an unsupervised cluster analysis leveraging p53 mutagenesis datasets (Kato et al., 2003 & Giacomelli et al., 2018) that revealed five TP53 mutational clusters with unique mutation patterns, structural features, and functional consequences. Stratifying germline carriers based on the five clusters exposed important clinical characteristics to consider for patient management, such as ages-of-onset, tumor type development, and survival outcomes. In particular, we discovered an osteosarcoma-prone subgroup comprised of monomeric mutant p53 carriers with aggressive cancer phenotypes. We also identified a cluster of TP53 variants found more often in non-cancer and healthy older populations, and carriers of these variants that developed cancer had less "LFS-like" phenotypes including an older age-of-onset and a significantly higher frequency of colorectal cancers. Remarkably, our TP53 variant clustering strategy could also stratify breast cancer survival among germline carriers. This work provides a new framework to delineate the LFS spectrum toward the development of machine learning-based approaches for personalized cancer surveillance plans. Citation Format: Nicholas W. Fischer, Brianne Laverty, Ran Kafri, Kara N. Maxwell, Emma R. Woodward, Christian Kratz, David Malkin. TP53 mutational clusters stratify the Li-Fraumeni syndrome spectrum [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6198.

oncology
Genetic and functional studies of a germline TP53 splicing mutation in a Li–Fraumeni-like family

J M Varley,P Chapman,G McGown,M Thorncroft,G R M White,M J Greaves,D Scott,A Spreadborough,K J Tricker,J M Birch,D G R Evans,R Reddel,R S Camplejohn,J Burn,J M Boyle

DOI: https://doi.org/10.1038/sj.onc.1201878

IF: 8.756

1998-06-25

Oncogene

Abstract:We report an extensive Li–Fraumeni-like family in which there is an unusual spectrum of tumours at relatively late onset. A germline TP53 splice donor mutation in exon 4 is present in all affected family members available for testing. The mutation abolishes correct splicing of intron 4 and techniques of RT–PCR have identified three different aberrant transcripts from the mutant TP53 allele. Using the yeast functional assay to analyse transcripts in cells from a number of family members with the mutant allele, TP53 appears wild-type. Functional studies have been carried out on cells from patients with and without cancer who carry the germline mutation, and on cells from unaffected individuals from the same family who do not carry the mutation. Using a number of functional endpoints known to distinguish between cells carrying mutant or wild-type TP53 alleles, we were unable to discriminate normal (wt/wt) from heterozygous (wt/mut) cells by lymphocyte apoptosis and fibroblast survival following low dose rate ionising radiation exposure. However germline mutation carriers show increased sensitivity to radiation-induced chromosome damage in the G2 phase of the cell cycle, and decreased transient and permanent G1 arrest. These studies demonstrate the importance of fully characterising the effects of TP53 germline mutations, and may explain some of the phenotypic features of this family.

oncology,genetics & heredity,biochemistry & molecular biology,cell biology
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation

J. Malcikova,E. Tausch,D. Rossi,L. A. Sutton,T. Soussi,T. Zenz,A. P. Kater,C. U. Niemann,D. Gonzalez,F. Davi,M. Gonzalez Diaz,C. Moreno,G. Gaidano,K. Stamatopoulos,R. Rosenquist,S. Stilgenbauer,P. Ghia,S. Pospisilova,on behalf of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network,

DOI: https://doi.org/10.1038/s41375-017-0007-7

2018-02-02

Leukemia

Abstract:In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. On these grounds, analysis of TP53 aberrations has been incorporated into routine clinical diagnostics to improve patient stratification and optimize therapeutic decisions. The predictive implications of TP53 aberrations have increasing significance in the era of novel targeted therapies, i.e., inhibitors of B-cell receptor (BcR) signaling and anti-apoptotic BCL2 family members, owing to their efficacy in patients with TP53 defects. In this report, the TP53 Network of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) presents updated recommendations on the methodological approaches for TP53 mutation analysis. Moreover, it provides guidance to ensure that the analysis is performed in a timely manner for all patients requiring treatment and that the data is interpreted and reported in a consistent, standardized, and accurate way. Since next-generation sequencing technologies are gaining prominence within diagnostic laboratories, this report also offers advice and recommendations for the interpretation of TP53 mutation data generated by this methodology.

oncology,hematology
Germline variant affecting p53β isoforms predisposes to familial cancer

Stephanie A Schubert,Dina Ruano,Sebastien M Joruiz,Jordy Stroosma,Nikolina Glavak,Anna Montali,Lia M Pinto,Mar Rodríguez-Girondo,Daniela Q C M Barge-Schaapveld,Maartje Nielsen,Bernadette P M van Nesselrooij,Arjen R Mensenkamp,Monique E van Leerdam,Thomas H Sharp,Hans Morreau,Jean-Christophe Bourdon,Noel F C C de Miranda,Tom van Wezel

DOI: https://doi.org/10.1038/s41467-024-52551-8

2024-09-18

Abstract:Germline and somatic TP53 variants play a crucial role during tumorigenesis. However, genetic variations that solely affect the alternatively spliced p53 isoforms, p53β and p53γ, are not fully considered in the molecular diagnosis of Li-Fraumeni syndrome and cancer. In our search for additional cancer predisposing variants, we identify a heterozygous stop-lost variant affecting the p53β isoforms (p.*342Serext*17) in four families suspected of an autosomal dominant cancer syndrome with colorectal, breast and papillary thyroid cancers. The stop-lost variant leads to the 17 amino-acid extension of the p53β isoforms, which increases oligomerization to canonical p53α and dysregulates the expression of p53's transcriptional targets. Our study reveals the capacity of p53β mutants to influence p53 signalling and contribute to the susceptibility of different cancer types. These findings underscore the significance of p53 isoforms and the necessity of comprehensive investigation into the entire TP53 gene in understanding cancer predisposition.
Characteristics of TP53 germline variants and their correlation with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients

Panwen Tian,Xiaoyan Zhang,Sheng Yang,Yu Fang,Hongling Yuan,Wei Li,Honglin Zhu,Fangping Zhao,Jinlei Ding,Yunshu Zhu,Sizhen Wang,Guochen Sun,Hongbin Ni,Tonghui Ma,Ting Lei

DOI: https://doi.org/10.1016/j.jgg.2021.12.012

IF: 5.723

2022-01-01

Journal of Genetics and Genomics

Abstract:Li-Fraumeni syndrome (LFS), a rare autosomal-dominant inheritance condition, is associated with a family cancer history as well as pathogenic/likely-pathogenic TP53 germline variants (P/LP TP53 GV). The current clinical methods for detecting LFS are limited. Here, we retrospectively investigate P/LP TP53 GV among Chinese cancer patients by next-generation sequencing and evaluate its relationship with a family cancer history. A total of 270 out of 19,226 cancer patients have TP53 GV, including 53 patients with P/LP TP53 GV. Patients with P/LP TP53 GV are mainly found in male with glioma, lung cancer or sarcoma. The median age of diagnosis for P/LP TP53 GV patients is significantly lower than that of non-P/LP TP53 GV patients (31-years vs. 53-years; P < 0.01). One LFS patient and 3 Li-Fraumeni-like syndrome (LFL) patients are among the 26 followed-up P/LP TP53 GV patients. Among 25 types of P/LP TP53 GV, the highest variant frequencies occurred at codon 175 and 248. p.M237I, p.R158H, p.C238Y and p.C275R, are firstly identified among the Chinese LFS/LFL patients. This study reports the (P/LP) TP53 GV characteristics of Chinese pan-cancer patients. These findings suggest analyzing the P/LP TP53 GV in cancer patients is an effective strategy for identifying cancer predisposition syndrome.

genetics & heredity,biochemistry & molecular biology
Characteristics of TP53 Germline Variants and Their Correlations with Li-Fraumeni Syndrome or Li-Fraumeni-like Syndrome in Chinese Tumor Patients

Panwen Tian,Xiaoyan Zhang,Sheng Yang,Yu Fang,Hongling Yuan,Wei Li,Honglin Zhu,Fangping Zhao,Jinlei Ding,Yunshu Zhu,Sizhen Wang,Guochen Sun,Hongbin Ni,Tonghui Ma,Ting Lei

DOI: https://doi.org/10.1016/j.jgg.2021.12.012

2022-01-01

Abstract:Li-Fraumeni syndrome (LFS), a rare autosomal-dominant inheritance condition, is associated with a family cancer history as well as pathogenic/likely-pathogenic TP53 germline variants (P/LP TP53 GV). The current clinical methods for detecting LFS are limited. Here, we retrospectively investigate P/LP TP53 GV among Chinese cancer patients by next-generation sequencing and evaluate its relationship with a family cancer history. A total of 270 out of 19,226 cancer patients have TP53 GV, including 53 patients with P/LP TP53 GV. Patients with P/LP TP53 GV are mainly found in male with glioma, lung cancer or sarcoma. The median age of diagnosis for P/LP TP53 GV patients is significantly lower than that of non-P/LP TP53 GV patients (31-years vs. 53-years; P < 0.01). One LFS patient and 3 Li-Fraumeni-like syndrome (LFL) patients are among the 26 followed-up P/LP TP53 GV patients. Among 25 types of P/LP TP53 GV, the highest variant frequencies occurred at codon 175 and 248. p.M237I, p.R158H, p.C238Y and p.C275R, are firstly identified among the Chinese LFS/LFL patients. This study reports the (P/LP) TP53 GV characteristics of Chinese pan-cancer patients. These findings suggest analyzing the P/LP TP53 GV in cancer patients is an effective strategy for identifying cancer predisposition syndrome.
Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers

Wensheng Zhang,Andrea Edwards,Erik K Flemington,Kun Zhang

DOI: https://doi.org/10.1177/1176935117691267

2017-02-20

Abstract:TP53 is the most frequently altered gene in human cancers. Numerous retrospective studies have related its mutation and abnormal p53 protein expression to poor patient survival. Nonetheless, the clinical significance of TP53 (p53) status has been a controversial issue. In this work, we aimed to characterize TP53 somatic mutations in tumor cells across multiple cancer types, primarily focusing on several less investigated features of the mutation spectra, and determine their prognostic implications. We performed an integrative study on the clinically annotated genomic data released by The Cancer Genome Atlas. Standard statistical methods, such as the Cox proportional hazards model and logistic regression, were used. This study resulted in several novel findings. They include the following: (1) similar to previously reported cases in breast cancer, the mutations in exons 1 to 4 of TP53 were more lethal than those in exons 5 to 9 for the patients with lung adenocarcinomas; (2) TP53 mutants tended to be negatively selected in mammalian evolution, but the evolutionary conservation had various clinical implications for different cancers; (3) conserved correlation patterns (ie, consistent co-occurrence or consistent mutual exclusivity) between TP53 mutations and the alterations in several other cancer genes (ie, PIK3CA, PTEN, KRAS, APC, CDKN2A, and ATM) were present in several cancers in which prognosis was associated with TP53 status and/or the mutational characteristics; (4) among TP53-mutated tumors, the total mutation burden in other driver genes was a predictive signature (P <.05, false discovery rate <0.11) for better patient survival outcome in several cancer types, including glioblastoma multiforme. Among these findings, the fourth is of special significance as it suggested the potential existence of epistatic interaction effects among the mutations in different cancer driver genes on clinical outcomes.
Formation of mineral phosphate microtubes in the presence of halophilic cyanobacteriumMicrocoleus chthonoplastes

I. Goncharova,L. Gerasimenko,G. Zavarzin,G. Ushatinskaya

DOI: https://doi.org/10.1007/BF01692874

IF: 2.343

1993-10-01

Current Microbiology

Abstract:
Diagnostic difficulties in rectosigmoid lesions.

V. Blaha,H. C. Saltzstein

DOI: https://doi.org/10.1007/BF03005027

1949-06-01

The American Journal of Digestive Diseases

Abstract:
EphA 3 , induced by PC1 / PrLZ , contributes to the malignant progression of prostate cancer

Ruiqin Wu,Hongtao Wang,Jian Wang,Peng Wang,Fang Huang,Bangxiang Xie,Yali Zhao,Li Shanhu,Jianguang Zhou

Abstract:Our previous study revealed the potential linkage of PC-1/PrLZ, a novel isolated prostate-specific gene, to the progression of prostate cancer (PCa) in vitro and in vivo. To gain more insight into the mechanism of PC-1-induced promotion of PCa, expression analysis of differential genes induced by PC-1 was scanned by microarray. Among all the differentially expressed genes, EphA3 was altered to the greatest extent. EphA3 has been identified to be associated with multiple tumor progression. However, little is known concerning the function of EphA3 in PCa. In the present study, we aimed to ascertain whether EphA3 is induced by PC-1 and the functional significance of EphA3 expression in PCa. We found that overexpression of PC-1 increased the amount of EphA3 and that knockdown of PC-1 led to a decrease in EphA3 in PCa cells. The functional significance and mechanisms by which EphA3 contributes to PCa was investigated in vitro using cell lines, and in vivo using a mouse model and clinical specimens. The results showed that EphA3 enhanced the proliferation and survival of LNCaP cells and suppression of EphA3 inhibited the survival of C4-2B cells. EphA3 enhanced the tumor development of LNCaP cells in null mice. A positive correlation between the levels of EphA3 and the Gleason grade of PCa was identified in clinical PCa specimens. In addition, cellular localization changed with Gleason grade. We further detected that EphA3 increased phosphorylation of Akt (Ser473 and Thr308), indicating that EphA3 activated the Akt pathway. Taken together, EphA3 was induced by PC-1 and contributed to the malignant progression of prostate cancer. Our results provide the first demonstration that EphA3 is a novel promoter of human prostate cancer development and progression.
Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne

K. Kast,K. Rhiem,M. Larsen,B. Wappenschmidt,R. Schmutzler

DOI: https://doi.org/10.1002/cam4.6920

IF: 4.711

2024-01-19

Cancer Medicine

Abstract:TP53‐associated tumor syndrome is a rare predisposition syndrome. Our analysis of the tumor spectrum and age of onset in 35 index patients supports the evidence for a less severe phenotype in families identified by gene panel testing for hereditary breast and ovarian cancer. Purpose Tumor protein p53 (TP53) pathogenic variant (PV) carriers are identified during genetic testing for hereditary causes of cancer. PVs in TP53 are associated with the Li‐Fraumeni syndrome (LFS), and thus, surveillance and preventive measures are important for TP53 PV carriers. However, the penetrance of TP53 PVs can be low if the Chompret criteria are not fulfilled. In this study, we compared the phenotypic characteristics of families that did and did not fulfill the LFS criteria according to Chompret. Methods The German Consortium for Hereditary Breast and Ovarian Cancer (GC‐HBOC) database was used to identify index patients with a likely pathogenic/pathogenic TP53 variant and their family members. The study investigated the type of variant, pedigree, age of onset, number of primary tumors, and histological type of BC. Results TP53 PV were present in the index cases of 35 families, 57% (20/35) of which fulfilled the Chompret criteria. The median age of onset at first BC diagnosis was lower in families that fulfilled the Chompret criteria compared to those who did not. Four of all diseased individuals were minors (4%; 4/105) when malignancy was first diagnosed. Sarcomas and brain tumors occurred in 10% (10/105) and in 7% (7/105) of all diseased persons, respectively. BC was the most frequently occurring first tumor (60%; 62/105) and additional malignancy (45%; 20/44) in this cohort. Subsequent malignancies developed in 31% (20/65) of the individuals who fulfilled the Chompret criteria compared with 15% (6/40) of those who did not. Conclusion The tumor spectrum and age of onset found in this study showed that tumors other than BC had low disease penetrance in TP53 PV carriers identified using the GC‐HBOC criteria for genetic testing.

oncology
Abstract 810: Enrichment and Screening of LFS Patients by Analyzing TP53 Germline Mutations of a Chinese Cancer Cohort

Changyu Lu,Fang Yu,Fachen Zhou,Yuntong Liu,Hongchuan Niu,Kai Li,Tao Ma,Xiaoyan Zhang

DOI: https://doi.org/10.1158/1538-7445.am2021-810

IF: 11.2

2021-01-01

Cancer Research

Abstract:Background: Li-Fraumeni syndrome (LFS) is a rare autosomal dominant inherited cancer syndrome; clinical diagnosis of it is mainly based on familial and personal history of cancer. Currently, most clinicians are lack of knowledge and experience of this rare disease, resulting in a difficulty to identify it. Consider that this is a rare tumor-type syndrome and 60-80% of the patients have germline variants of TP53, herein, we analyzed germline pathogenic/likely pathogenic (P/LP) TP53 variants in a Chinese tumor cohort with unknown familial history, and successfully established an analysis process to better screen for LFS patients. Methods: We retrospectively analyzed the germline TP53 mutations of a total of 19,226 Chinese tumor patients with unknown familial history. The screening process of LFS patients was as follows: 1) Germline P/LP TP53 variants must satisfy P/LP in any of the three databases: UMD_TP53, ClinVar or HGMD. It also must be defined as “non-functional” mutations in IARC database which includes all TP53 germline mutations of clinically determined LFS patients; 2) Follow up the familial and personal histories of patients with germline P/LP TP53 variants. Results: After screening, 26 germline P/LP TP53 variants were obtained, which involved 54 patients, mainly in brain cancer (34 pts) and lung cancer (9 pts). The median age of these 34 brain cancer patients was younger than that of 5,845 brain cancer patients in the cohort (28 vs. 44 year-old). Yet no such phenomenon was observed in lung cancer. It is necessary for young brain cancer patients to detect germline TP53 mutations. We then analyzed the relationship between germline P/LP TP53 variants and LFS in the 54 patients. According to the Chompret criterion of LFS, two patients who respectively had adrenocortical carcinoma (R175H of TP53) and choroid plexus carcinoma (G245S) were both LFS patients regardless of whether they had a familial history. We finally obtained follow-up information of 17 patients. Among them, four brain cancer patients (R248Q/R158H/C238Y/M237I), one lung cancer patient (R175H) and one leiomyosarcoma patient (R213Q) had family members who had cancers before 46-year-old. Another brain cancer patient (G245S; 1/17) had more than one cancer before 46-years-old. Hence, these seven patients (7/17; 41.18%) were also defined as LFS patients by the Chompret criterion. In total, 9 patients had LFS. It shows a high positive detection rate in our cohort by our analysis process. Conclusions: We have established an analysis process based on germline P/LP TP53 variants, which can efficiently screen for LFS patients in clinic. Citation Format: Changyu Lu, Yu Fang, Fachen Zhou, Yuntong Liu, Hongchuan Niu, Kai Li, Tonghui Ma, Xiaoyan Zhang. Enrichment and screening of LFS patients by analyzing TP53 germline mutations of a Chinese cancer cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 810.

Selective adaptation with reversible figures: Don’t change that channel

Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP: Report from an International DLBCL Rituximab-CHOP Consortium Program Study

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—2024 update

UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants

Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis

TP53 Germline Variations Influence the Predisposition and Prognosis of Acute Lymphoblastic Leukemia in Children

Germline p.R181H variant in TP53 in a family exemplifying the genotype-phenotype correlations in Li-Fraumeni syndrome

Case report: TP53 c.848G>A germline mutation as a possible screening target at initial diagnosis for acute lymphoblastic leukemia

Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum

Abstract 6198: TP53 mutational clusters stratify the Li-Fraumeni syndrome spectrum

Genetic and functional studies of a germline TP53 splicing mutation in a Li–Fraumeni-like family

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation

Germline variant affecting p53β isoforms predisposes to familial cancer

Characteristics of TP53 germline variants and their correlation with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients

Characteristics of TP53 Germline Variants and Their Correlations with Li-Fraumeni Syndrome or Li-Fraumeni-like Syndrome in Chinese Tumor Patients

Significant Prognostic Features and Patterns of Somatic TP53 Mutations in Human Cancers

Formation of mineral phosphate microtubes in the presence of halophilic cyanobacteriumMicrocoleus chthonoplastes

Diagnostic difficulties in rectosigmoid lesions.

EphA 3 , induced by PC1 / PrLZ , contributes to the malignant progression of prostate cancer

Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian Cancer, Cologne

Abstract 810: Enrichment and Screening of LFS Patients by Analyzing TP53 Germline Mutations of a Chinese Cancer Cohort